foxo4-dri senolytic human trial 2024 The disordered p53 transactivation domain is the target of FOXO4 and the compound cytoskeletal-research SS-31 (Elamipretide) 10mg – BPC-157:10mg Vial
SKU: 83908919572
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 13 - Sep 18























